<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949975</url>
  </required_header>
  <id_info>
    <org_study_id>D0520C00012</org_study_id>
    <nct_id>NCT00949975</nct_id>
  </id_info>
  <brief_title>A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium</brief_title>
  <official_title>A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multinational, Phase IIb Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at 3 Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668
      at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on
      lung function and symptoms of COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Pre-bronchodilator FEV1 (L)</measure>
    <time_frame>Day 1</time_frame>
    <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>End-value Pre-bronchodilator FEV1 (L)</measure>
    <time_frame>Measured at clinic visits: 1, 4, 8 and 12 weeks</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator FEV1 (L) - Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator FEV1 (L) - End-value</measure>
    <time_frame>Measured at clinic visits: 1, 4, 8 and 12 weeks</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator FVC (L) - Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Forced Vital Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator FVC (L) - End-value</measure>
    <time_frame>Measured at clinic visits: 1, 4, 8 and 12 weeks</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator FVC (L) - Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Forced Vital Capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator FVC (L) - End-value</measure>
    <time_frame>Measured at clinic visits: 1, 4, 8 and 12 weeks</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator IC (L) - Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Inspiratory Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator IC (L) - End-value</measure>
    <time_frame>Measured at clinic visits: 1, 4, 8 and 12 weeks</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator IC (L) - Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Inspiratory Capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator IC (L) - End-value</measure>
    <time_frame>Measured at clinic visits: 1, 4, 8 and 12 weeks</time_frame>
    <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF - Baseline Measured by Patient at Home (L/Min) in the Morning</measure>
    <time_frame>Baseline</time_frame>
    <description>Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each morning.Baseline is the mean of last 10 days of data before start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF - End-value Measured by Patient at Home (L/Min) in the Morning</measure>
    <time_frame>Last 6 weeks on treatment</time_frame>
    <description>Peak Expiratory Flow (L/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 - Baseline Measured by Patient at Home (L) in the Morning</measure>
    <time_frame>Baseline</time_frame>
    <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each morning.Baseline is the mean of last 10 days of data before start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 - End-value Measured by Patient at Home (L) in the Morning</measure>
    <time_frame>Last 6 weeks on treatment</time_frame>
    <description>Forced Expiratory Volume in 1 second (L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EXACT - Baseline Total Score</measure>
    <time_frame>Baseline</time_frame>
    <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status)scale). Baseline is the mean of last 10 days of data before start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EXACT - End-value Total Score</measure>
    <time_frame>Measured daily in the evening for 12 weeks</time_frame>
    <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status)scale). Last 6 weeks on treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCSS - Baseline Total Score</measure>
    <time_frame>Baseline</time_frame>
    <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status)scale).Baseline is the mean of last 10 days of data before start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCSS - End-value Total Score</measure>
    <time_frame>Measured daily in the evening for 12 weeks</time_frame>
    <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0(best health status) to 12(worst possible status)scale). Last 6 weeks on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Colour - Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Colour - End Value</measure>
    <time_frame>Measured at clinic visits:1, 4, 8 and 12 weeks</time_frame>
    <description>Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status).End of treatment week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Reliever Medication</measure>
    <time_frame>Last 6 weeks on treatment</time_frame>
    <description>Daily average of number of inhalations of reliever medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-minute Walk Test - Distance Walked at Baseline (m)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-minute Walk Test - End-value Distance Walked (m)</measure>
    <time_frame>Measured Day 1 and 12 weeks</time_frame>
    <description>distance walked on vist 6 - last on treatment clinic visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St George's Respiratory Questionnaire (COPD) - Overall Score at Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a % scale from 0 (best health status) to 100(worst possible status)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St George's Respiratory Questionnaire (COPD) - End-value Overall Score</measure>
    <time_frame>Measured Day 1 and 12 weeks</time_frame>
    <description>St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a % scale from 0 (best health status) to 100(worst possible status)).questionaire assessed on vist 6 -( last on treatment clinic visit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbations - Clinic Defined</measure>
    <time_frame>Duration of the the treatment period - 12 weeks</time_frame>
    <description>Number of patients having a clinic defined disease exacerbation</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">838</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AZD9668 active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AZD9668 active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AZD9668 active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AZD9668 placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9668</intervention_name>
    <description>2 x 30 mg oral tablets twice daily (bid) for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9668</intervention_name>
    <description>2 x 10 mg oral tablets twice daily (bid) for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9668</intervention_name>
    <description>2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9668 Placebo</intervention_name>
    <description>2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD with symptoms over 1 year

          -  Smokers or ex-smokers

          -  Males or post-menopausal females between 40 and 80 years old

          -  Able to use electronic devices

        Exclusion Criteria:

          -  Past history or current evidence of clinically significant heart disease

          -  Current diagnosis of asthma

          -  Patients who require long term oxygen therapy

          -  Treatment with antibiotics within 4 weeks of study visit 1b
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Volgemeier, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director der Klinik fur Innere Medizin mit Schwerpunkt Pneumologie-Universitatsklinikum GieBen und Marburg, D-35043 Marburg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jefferson Hills</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glebe</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Carina Heights</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daw Park</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Antigonish</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grimsby</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Malbaie</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-leonard</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seto</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Noda</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Touon</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yukuhashi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nihonmatsu</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ukyo-ku, Kyoto</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saeki</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kishiwada</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kita-ku, Sakai</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsue</city>
        <state>Shimane</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nakano-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tanabe</city>
        <state>Wakayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bunkyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uijeongbu</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wonju</city>
        <state>Kangwon-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lipa City, Batangas</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Checiny</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrow Wielkopolski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Proszowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tczew</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zawadzkie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barnaul</city>
        <state>Russia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Russia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <state>Russia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>Russia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <state>Russia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St.petersburg</city>
        <state>Russia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bojnice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nove Mesto Nad Vahom</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poprad</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trnava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zvolen</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tao-yuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lugansk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2009</study_first_posted>
  <results_first_submitted>January 24, 2012</results_first_submitted>
  <results_first_submitted_qc>June 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2012</results_first_posted>
  <last_update_submitted>June 19, 2012</last_update_submitted>
  <last_update_submitted_qc>June 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic</keyword>
  <keyword>Obstructive</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>Lung</keyword>
  <keyword>Respiratory disease</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety and tolerability</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled 13 July 2009. Last patient completed 05 August 2010. Study conducted at 138 centres in 12 countries (Australia, Canada, Germany, Japan, Korea, Philippines, Poland, Russia, Slovakia, Taiwan, Ukraine and US)</recruitment_details>
      <pre_assignment_details>Patients were stabilised on maintenance therapy (tiotropium, 18 micrograms od) during a 2-week run-in period before randomisation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>5 mg AZD9668</title>
          <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>20 mg AZD9668</title>
          <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>60 mg AZD9668</title>
          <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Matched Placebo Tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="206"/>
                <participants group_id="P3" count="202"/>
                <participants group_id="P4" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="177"/>
                <participants group_id="P3" count="183"/>
                <participants group_id="P4" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Voluntary discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Safety reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study-specific criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect enrolment</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>5 mg AZD9668</title>
          <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>20 mg AZD9668</title>
          <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>60 mg AZD9668</title>
          <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Matched Placebo Tablets</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="212"/>
            <count group_id="B2" value="206"/>
            <count group_id="B3" value="202"/>
            <count group_id="B4" value="218"/>
            <count group_id="B5" value="838"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="42" upper_limit="80"/>
                    <measurement group_id="B2" value="63" lower_limit="42" upper_limit="79"/>
                    <measurement group_id="B3" value="61" lower_limit="40" upper_limit="79"/>
                    <measurement group_id="B4" value="62" lower_limit="41" upper_limit="80"/>
                    <measurement group_id="B5" value="62" lower_limit="40" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="165"/>
                    <measurement group_id="B5" value="639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline Pre-bronchodilator FEV1 (L)</title>
        <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Pre-bronchodilator FEV1 (L)</title>
          <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.471"/>
                    <measurement group_id="O2" value="1.47" spread="0.468"/>
                    <measurement group_id="O3" value="1.50" spread="0.512"/>
                    <measurement group_id="O4" value="1.51" spread="0.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>End-value Pre-bronchodilator FEV1 (L)</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>Measured at clinic visits: 1, 4, 8 and 12 weeks</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>End-value Pre-bronchodilator FEV1 (L)</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.018" lower_limit="0.018"/>
                    <measurement group_id="O2" value="1.47" spread="0.018" lower_limit="0.018"/>
                    <measurement group_id="O3" value="1.46" spread="0.018" lower_limit="0.018"/>
                    <measurement group_id="O4" value="1.47" spread="0.018" lower_limit="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator FEV1 (L) - Baseline</title>
        <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator FEV1 (L) - Baseline</title>
          <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.501"/>
                    <measurement group_id="O2" value="1.64" spread="0.472"/>
                    <measurement group_id="O3" value="1.65" spread="0.516"/>
                    <measurement group_id="O4" value="1.69" spread="0.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator FEV1 (L) - End-value</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>Measured at clinic visits: 1, 4, 8 and 12 weeks</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator FEV1 (L) - End-value</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="0.017" lower_limit="0.017"/>
                    <measurement group_id="O2" value="1.63" spread="0.017" lower_limit="0.017"/>
                    <measurement group_id="O3" value="1.63" spread="0.017" lower_limit="0.017"/>
                    <measurement group_id="O4" value="1.62" spread="0.017" lower_limit="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator FVC (L) - Baseline</title>
        <description>Forced Vital Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator FVC (L) - Baseline</title>
          <description>Forced Vital Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" spread="0.850"/>
                    <measurement group_id="O2" value="3.01" spread="0.739"/>
                    <measurement group_id="O3" value="3.06" spread="0.856"/>
                    <measurement group_id="O4" value="3.04" spread="0.754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator FVC (L) - End-value</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>Measured at clinic visits: 1, 4, 8 and 12 weeks</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator FVC (L) - End-value</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" spread="0.026" lower_limit="0.026"/>
                    <measurement group_id="O2" value="3.05" spread="0.026" lower_limit="0.026"/>
                    <measurement group_id="O3" value="3.02" spread="0.026" lower_limit="0.026"/>
                    <measurement group_id="O4" value="3.02" spread="0.025" lower_limit="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator FVC (L) - Baseline</title>
        <description>Forced Vital Capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator FVC (L) - Baseline</title>
          <description>Forced Vital Capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="0.914"/>
                    <measurement group_id="O2" value="3.24" spread="0.723"/>
                    <measurement group_id="O3" value="3.24" spread="0.885"/>
                    <measurement group_id="O4" value="3.27" spread="0.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator FVC (L) - End-value</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>Measured at clinic visits: 1, 4, 8 and 12 weeks</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator FVC (L) - End-value</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="0.023" lower_limit="0.023"/>
                    <measurement group_id="O2" value="3.26" spread="0.024" lower_limit="0.024"/>
                    <measurement group_id="O3" value="3.24" spread="0.024" lower_limit="0.024"/>
                    <measurement group_id="O4" value="3.22" spread="0.023" lower_limit="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator IC (L) - Baseline</title>
        <description>Inspiratory Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator IC (L) - Baseline</title>
          <description>Inspiratory Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="0.680"/>
                    <measurement group_id="O2" value="2.14" spread="0.563"/>
                    <measurement group_id="O3" value="2.15" spread="0.662"/>
                    <measurement group_id="O4" value="2.17" spread="0.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator IC (L) - End-value</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>Measured at clinic visits: 1, 4, 8 and 12 weeks</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator IC (L) - End-value</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="0.027" lower_limit="0.027"/>
                    <measurement group_id="O2" value="2.15" spread="0.028" lower_limit="0.028"/>
                    <measurement group_id="O3" value="2.16" spread="0.027" lower_limit="0.027"/>
                    <measurement group_id="O4" value="2.15" spread="0.026" lower_limit="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator IC (L) - Baseline</title>
        <description>Inspiratory Capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator IC (L) - Baseline</title>
          <description>Inspiratory Capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="0.709"/>
                    <measurement group_id="O2" value="2.30" spread="0.601"/>
                    <measurement group_id="O3" value="2.28" spread="0.677"/>
                    <measurement group_id="O4" value="2.32" spread="0.628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator IC (L) - End-value</title>
        <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
        <time_frame>Measured at clinic visits: 1, 4, 8 and 12 weeks</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator IC (L) - End-value</title>
          <description>End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="0.025" lower_limit="0.025"/>
                    <measurement group_id="O2" value="2.30" spread="0.025" lower_limit="0.025"/>
                    <measurement group_id="O3" value="2.31" spread="0.025" lower_limit="0.025"/>
                    <measurement group_id="O4" value="2.30" spread="0.025" lower_limit="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF - Baseline Measured by Patient at Home (L/Min) in the Morning</title>
        <description>Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each morning.Baseline is the mean of last 10 days of data before start of treatment</description>
        <time_frame>Baseline</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>PEF - Baseline Measured by Patient at Home (L/Min) in the Morning</title>
          <description>Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each morning.Baseline is the mean of last 10 days of data before start of treatment</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.33" spread="83.177"/>
                    <measurement group_id="O2" value="219.86" spread="90.395"/>
                    <measurement group_id="O3" value="216.99" spread="91.299"/>
                    <measurement group_id="O4" value="221.79" spread="89.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF - End-value Measured by Patient at Home (L/Min) in the Morning</title>
        <description>Peak Expiratory Flow (L/min)</description>
        <time_frame>Last 6 weeks on treatment</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>PEF - End-value Measured by Patient at Home (L/Min) in the Morning</title>
          <description>Peak Expiratory Flow (L/min)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214.30" spread="2.899" lower_limit="2.899"/>
                    <measurement group_id="O2" value="214.55" spread="2.920" lower_limit="2.920"/>
                    <measurement group_id="O3" value="212.35" spread="2.944" lower_limit="2.944"/>
                    <measurement group_id="O4" value="220.47" spread="2.840" lower_limit="2.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 - Baseline Measured by Patient at Home (L) in the Morning</title>
        <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each morning.Baseline is the mean of last 10 days of data before start of treatment</description>
        <time_frame>Baseline</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 - Baseline Measured by Patient at Home (L) in the Morning</title>
          <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each morning.Baseline is the mean of last 10 days of data before start of treatment</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.521"/>
                    <measurement group_id="O2" value="1.34" spread="0.444"/>
                    <measurement group_id="O3" value="1.36" spread="0.507"/>
                    <measurement group_id="O4" value="1.38" spread="0.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 - End-value Measured by Patient at Home (L) in the Morning</title>
        <description>Forced Expiratory Volume in 1 second (L)</description>
        <time_frame>Last 6 weeks on treatment</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 - End-value Measured by Patient at Home (L) in the Morning</title>
          <description>Forced Expiratory Volume in 1 second (L)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.018" lower_limit="0.018"/>
                    <measurement group_id="O2" value="1.35" spread="0.018" lower_limit="0.018"/>
                    <measurement group_id="O3" value="1.33" spread="0.018" lower_limit="0.018"/>
                    <measurement group_id="O4" value="1.34" spread="0.018" lower_limit="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EXACT - Baseline Total Score</title>
        <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status)scale). Baseline is the mean of last 10 days of data before start of treatment.</description>
        <time_frame>Baseline</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>EXACT - Baseline Total Score</title>
          <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status)scale). Baseline is the mean of last 10 days of data before start of treatment.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.17" spread="10.109"/>
                    <measurement group_id="O2" value="42.38" spread="8.166"/>
                    <measurement group_id="O3" value="42.37" spread="9.320"/>
                    <measurement group_id="O4" value="40.95" spread="9.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EXACT - End-value Total Score</title>
        <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status)scale). Last 6 weeks on treatment.</description>
        <time_frame>Measured daily in the evening for 12 weeks</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>EXACT - End-value Total Score</title>
          <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status)scale). Last 6 weeks on treatment.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.97" spread="0.545" lower_limit="0.545"/>
                    <measurement group_id="O2" value="39.72" spread="0.543" lower_limit="0.543"/>
                    <measurement group_id="O3" value="40.59" spread="0.552" lower_limit="0.552"/>
                    <measurement group_id="O4" value="39.71" spread="0.533" lower_limit="0.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BCSS - Baseline Total Score</title>
        <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status)scale).Baseline is the mean of last 10 days of data before start of treatment</description>
        <time_frame>Baseline</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>BCSS - Baseline Total Score</title>
          <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status)scale).Baseline is the mean of last 10 days of data before start of treatment</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" spread="1.954"/>
                    <measurement group_id="O2" value="4.66" spread="1.526"/>
                    <measurement group_id="O3" value="4.79" spread="1.756"/>
                    <measurement group_id="O4" value="4.48" spread="1.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BCSS - End-value Total Score</title>
        <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0(best health status) to 12(worst possible status)scale). Last 6 weeks on treatment</description>
        <time_frame>Measured daily in the evening for 12 weeks</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>BCSS - End-value Total Score</title>
          <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0(best health status) to 12(worst possible status)scale). Last 6 weeks on treatment</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="0.098" lower_limit="0.098"/>
                    <measurement group_id="O2" value="4.03" spread="0.099" lower_limit="0.099"/>
                    <measurement group_id="O3" value="4.25" spread="0.100" lower_limit="0.100"/>
                    <measurement group_id="O4" value="4.20" spread="0.096" lower_limit="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Colour - Baseline</title>
        <description>Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status).</description>
        <time_frame>Baseline</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Colour - Baseline</title>
          <description>Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="188"/>
                <count group_id="O4" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="1.069"/>
                    <measurement group_id="O2" value="2.34" spread="1.137"/>
                    <measurement group_id="O3" value="2.13" spread="0.956"/>
                    <measurement group_id="O4" value="2.16" spread="1.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Colour - End Value</title>
        <description>Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status).End of treatment week 12</description>
        <time_frame>Measured at clinic visits:1, 4, 8 and 12 weeks</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Colour - End Value</title>
          <description>Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status).End of treatment week 12</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="188"/>
                <count group_id="O4" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.062" lower_limit="0.062"/>
                    <measurement group_id="O2" value="2.03" spread="0.065" lower_limit="0.065"/>
                    <measurement group_id="O3" value="2.20" spread="0.063" lower_limit="0.063"/>
                    <measurement group_id="O4" value="2.11" spread="0.062" lower_limit="0.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Reliever Medication</title>
        <description>Daily average of number of inhalations of reliever medication</description>
        <time_frame>Last 6 weeks on treatment</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Reliever Medication</title>
          <description>Daily average of number of inhalations of reliever medication</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Inhalations</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28" spread="0.173" lower_limit="0.173"/>
                    <measurement group_id="O2" value="4.20" spread="0.175" lower_limit="0.175"/>
                    <measurement group_id="O3" value="4.65" spread="0.175" lower_limit="0.175"/>
                    <measurement group_id="O4" value="4.56" spread="0.170" lower_limit="0.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six-minute Walk Test - Distance Walked at Baseline (m)</title>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Six-minute Walk Test - Distance Walked at Baseline (m)</title>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="184"/>
                <count group_id="O3" value="191"/>
                <count group_id="O4" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386.2" spread="125.22"/>
                    <measurement group_id="O2" value="402.2" spread="111.98"/>
                    <measurement group_id="O3" value="384.9" spread="115.50"/>
                    <measurement group_id="O4" value="386.0" spread="132.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six-minute Walk Test - End-value Distance Walked (m)</title>
        <description>distance walked on vist 6 - last on treatment clinic visit</description>
        <time_frame>Measured Day 1 and 12 weeks</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Six-minute Walk Test - End-value Distance Walked (m)</title>
          <description>distance walked on vist 6 - last on treatment clinic visit</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>m</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="184"/>
                <count group_id="O3" value="191"/>
                <count group_id="O4" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396.7" spread="4.74" lower_limit="4.74"/>
                    <measurement group_id="O2" value="397.8" spread="4.87" lower_limit="4.87"/>
                    <measurement group_id="O3" value="411.2" spread="4.76" lower_limit="4.76"/>
                    <measurement group_id="O4" value="409.5" spread="4.61" lower_limit="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St George's Respiratory Questionnaire (COPD) - Overall Score at Baseline</title>
        <description>St George’s Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a % scale from 0 (best health status) to 100(worst possible status)).</description>
        <time_frame>Day 1</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>St George's Respiratory Questionnaire (COPD) - Overall Score at Baseline</title>
          <description>St George’s Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a % scale from 0 (best health status) to 100(worst possible status)).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="194"/>
                <count group_id="O4" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.98" spread="18.276"/>
                    <measurement group_id="O2" value="51.98" spread="18.207"/>
                    <measurement group_id="O3" value="52.97" spread="18.234"/>
                    <measurement group_id="O4" value="51.41" spread="18.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St George's Respiratory Questionnaire (COPD) - End-value Overall Score</title>
        <description>St George’s Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a % scale from 0 (best health status) to 100(worst possible status)).questionaire assessed on vist 6 -( last on treatment clinic visit)</description>
        <time_frame>Measured Day 1 and 12 weeks</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>St George's Respiratory Questionnaire (COPD) - End-value Overall Score</title>
          <description>St George’s Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a % scale from 0 (best health status) to 100(worst possible status)).questionaire assessed on vist 6 -( last on treatment clinic visit)</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="194"/>
                <count group_id="O4" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.50" spread="1.014" lower_limit="1.014"/>
                    <measurement group_id="O2" value="49.49" spread="1.049" lower_limit="1.049"/>
                    <measurement group_id="O3" value="47.93" spread="1.023" lower_limit="1.023"/>
                    <measurement group_id="O4" value="46.35" spread="0.984" lower_limit="0.984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exacerbations - Clinic Defined</title>
        <description>Number of patients having a clinic defined disease exacerbation</description>
        <time_frame>Duration of the the treatment period - 12 weeks</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg AZD9668</title>
            <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>20 mg AZD9668</title>
            <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>60 mg AZD9668</title>
            <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matched Placebo Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Exacerbations - Clinic Defined</title>
          <description>Number of patients having a clinic defined disease exacerbation</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>5 mg AZD9668</title>
          <description>AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>20 mg AZD9668</title>
          <description>AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>60 mg AZD9668</title>
          <description>AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Matched Placebo Tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>ACUTE SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>BLOOD UREA INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM T WAVE INVERSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>URETERIC OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>'RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

